A new analysis from Novo Nordisk indicates that patients using its obesity drug Wegovy experienced a 33% reduced risk of dying from COVID-19 compared to those on placebo.
Researchers found that not only did semaglutide users have a significantly lower risk of COVID-19 mortality, but they also experienced a 19% reduction in death from any cause, an unusual outcome for drug trials.
The findings suggest that the protective effects of Wegovy were evident even before participants began to lose weight, indicating an early response mechanism at play.
The Harvard-led study, which analyzed over 17,600 non-diabetic obese patients during the pandemic, highlights the adaptability and innovation in research methodologies during unprecedented times.
Collection
[
|
...
]